EGF and breast cancer: Indeed, the silencing of ARF6 or GEP100 inhibits EGF-induced matrigel invasion by highly invasive human breast cancer cell lines, and further prevents ARF6 activation in the absence of GEP100, indicating that GEP100 contributes to the invasive properties of tumor cells through the regulation of ARF6 activity.